Drug Type Antibody drug conjugate (ADC) |
Synonyms- |
Target |
Action inhibitors, stimulants |
Mechanism TOP1 inhibitors(DNA topoisomerase I inhibitors), Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC11H22N4O4 |
InChIKeyAGGWFDNPHKLBBV-YUMQZZPRSA-N |
CAS Registry159858-33-0 |


| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Breast Cancer | Preclinical | United States | 22 Apr 2026 | |
| Breast Cancer | Preclinical | United States | 22 Apr 2026 | |
| Colorectal Cancer | Preclinical | United States | 22 Apr 2026 | |
| Colorectal Cancer | Preclinical | United States | 22 Apr 2026 | |
| Esophageal Carcinoma | Preclinical | United States | 22 Apr 2026 | |
| Esophageal Carcinoma | Preclinical | United States | 22 Apr 2026 | |
| Lung Cancer | Preclinical | United States | 22 Apr 2026 | |
| Lung Cancer | Preclinical | United States | 22 Apr 2026 | |
| Pancreatic Cancer | Preclinical | United States | 22 Apr 2026 | |
| Pancreatic Cancer | Preclinical | United States | 22 Apr 2026 |






